OBJECTIVES: Pure bronchioloalveolar carcinoma (BAC) is considered the early stage of lung adenocarcinoma, and is even regarded as lung adenocarcinoma in situ. This study was designed to investigate the differences in the gene expression of pure BAC and that of adenocarcinoma with bronchioloalveolar features and explore the mechanism of BAC progression to adenocarcinoma with bronchioloalveolar features METHODS: Total RNA was extracted from 16 tissue specimens. Expression analysis was carried out using Agilent 4 × 44 k arrays. Gene ontology analysis was used to define pathways altered in bronchioloalveolar progression. Differentially expressed candidate genes were validated using quantitative real-time PCR. The statistical analysis was carried out according to the methods of the paired t-test.
INTRODUCTION
Liebow first coined the term bronchioloalveolar carcinoma (BAC) in 1960, describing the tumour as a well-differentiated adenocarcinoma with neoplastic cells spreading along the alveoli with little stromal reaction, no invasion and preservation of alveolar architecture. Based on the 2004 WHO classification guidelines, pure BAC has a distinct histological pattern of tumour cells growing along a pre-existing alveolar framework without evidence of stromal, pleural or vascular invasion. However, some invasive adenocarcinomas, classified as mixed type, may have components or large areas of BAC-like pattern [1] . Whereas pure BAC is uncommon, adenocarcinoma with BAC features (AWBF) is a common tumour. AWBF comprises 50% of all adenocarcinomas. Patients with pure BAC have much better chances of surviving than those with AWBF. Some scholars have suggested that atypical adenomatous hyperplasia, pure BAC, AWBF and solid adenocarcinoma might represent the developmental sequence of bronchioloalveolar stem cells rather than a classification system [2, 3] . Stepwise progression from atypical adenomatous hyperplasia through BAC to invasive lung AWBFs was thus proposed. The presence of some abnormal signal pathways in the progression from pure BAC to AWBFs, and an association between some genes in these pathways and the poor prognosis of AWBFs were hypothesized. To our knowledge, this is the first study to have used the dual microarray-Power-Blot approach in screening gene alterations to elucidate the mechanisms of action of resveratrol in lung cancer prevention/therapy.
MATERIALS AND METHODS

Biological samples
Sixteen fresh BAC tissues ( pure tumours) were collected between 2009 and 2010 at the time of operation and snap frozen in liquid nitrogen (shown in Table 1 ). The tumours were classified according to the 2004 World Health Organization classification system [3] , using the Tumour, Lymph Node, Metastasis staging system. Eight patients were diagnosed with AWBFs, when they were found to have not only prominent non-mucinous BAC-like patterns (−55% of the tumour) but also frank invasive adenocarcinomas of other histological types (acinar, papillary or solid). Eight others were diagnosed as having non-invasive BAC. Written informed consent was obtained from all patients. This study was approved by the Clinical Trials Review Board of the Cancer Institute and Hospital of Tianjin Medical University.
RNA extraction
RNA was extracted with TRIZOL Reagent (Invitrogen Gaithersburg, MD, USA) and purified using an RNeasy MINI Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. RNA quality was assessed via formaldehyde agarosegel electrophoresis and quantified spectrophotometrically.
Microarray hybridization
One microgram of RNA was used as a template for cDNA preparation prior to hybridization to Agilent 4 × 44k whole human genome arrays. Briefly, 2.5 μg of aRNA and that of Universal Human Reference RNA (Stratagene La Jolla, CA, USA) were labelled in reverse transcription with Cy3-deoxyuridinetriphate (dUTP) and Cy5-dUTP using the Agilent low RNA input linear amplification kit and hybridized overnight at 65°C to Agilent 4 × 44 k whole human genome arrays. Arrays were washed and scanned using an Agilent scanner (Agilent Microarray Scanner-G2565BA, Agilent Technologies).
Data analysis
The Feature Extraction Software v9.1.3.1 (Agilent Technologies) was used to extract and analyse the assay signals and subsequently determine the signal-to-noise ratios from the microarray images. The transferred data files were analysed with Avadis software (StrandGenomics, Bangalore, India). The assay signals of the remaining sets for 99.5% of the genes were log-transformed and they were further filtered using a Standard Expression Array System signal-to-noise threshold [signal-to-noise ratio, >3 (in at least one sample)] and a flag threshold (<100) to select the differentially expressed genes. The filtered genes were normalized via the median normalization method. The significant genes were calculated using two-sample t-tests [genes with no significant (P > 0.05) were excluded] and the fold change (FC) method [genes with no significant (FC <2) were excluded]. Multiple testing was performed to minimize the number of false-positive genes. The FC was calculated for the average of each group. A functional category was assigned to each signature gene. Pathway analysis was done with Ingenuity software. Biological networks identified by the program were assessed in the context of general functional classes by GO ontology classification. A pathway that had a hypergeometric distribution probability <0.05 and was hit by two or more genes from 43 genes was selected and investigated.
Confirmation of microarray data by real-time reverse transcriptase polymerase chain reaction Validation of microarray results was performed on 60 cases (30 specimen pairs). Four differentially expressed genes were validated by qRT-PCR. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene served as the housekeeping gene. Quantitative PCR amplications were performed in triplicate using the SYBR Green I assay in an Option II detection system (MJ Research, Inc., Waltham, MA, USA), gene chip assays were performed with an ABI 7500 system (Applied Biosystems, Foster City, CA, USA) under SYBR Green PCR conditions for 35 cycles ( primers shown in Table 2 ). qRT-PCR data for each sample were normalized using expression of the housekeeping gene. Graphs were prepared from normalized data relative to GAPDH.
Statistical analysis
Cycle threshold values were directly used as a measure of mRNA expression, without conversion into relative copy numbers. Data were expressed as mean ± SE. Paired t-test was used to analyse differences in mRNA expression between pure BAC and AWBF in microarray and real-time RT-PCR analyses. The calculation was performed using the SPSS for Windows statistical software package (SPSS Inc., Chicago, IL, USA).
RESULTS
Identification of differentially expressed genes and pathways in the AWBFs and pure specimens
RNAs were hybridized to Agilent 60-mer oligonucleotide 4 × 44 k Whole Human Genome expression microarrays, which represent 41 000 unique genes and transcripts. Genes for which the signal-to-noise ratio was <3 in >70% of entire sample, and in which the flag value was more than 100, were selected to minimize the number of false-positive genes; 43 genes that were considered candidate marker genes for tumour progression and metastasis were found to be differentially expressed between the pure BAC specimens and the AWBFs specimens, with their difference in the signal intensity ratio being >2-fold (t-test, P < 0.00001). Twenty-three overexpressed genes had previously been listed in GenBank (Table 3) , and 20 underexpressed ones had also previously been listed in GenBank (Table 4) . For a given gene signature, a pathway that had a hypergeometric distribution probability smaller than 0.05 and included two or more genes was considered an over-represented pathway. The 'inclusion of two or more genes' as a selection criterion in addition to the statistical significance was to avoid selecting statistically significant pathways containing only one gene in the signature. The function of the 43 genes in the signature was analysed to relate the genes to eight biological pathways (data not shown), and the mitogen-activated protein kinase (MAPK) pathway was the most prominent ( Fig. 1) .
Validation of the microarray data by real-time reverse transcriptase polymerase chain reaction
To confirm the results obtained by microarray, we selected interesting genes [claudin 18 (CLDN18), fibroblast growth factor receptor 1 (FGFR1), ataxia telangiectasia and Rad3 related (ATR), activating transcription factor-2 (ATF-2)] for real-time RT-PCR analysis to estimate expression differences between BAC and AWBF in 60 cases. In accordance with the microarray data, CLDN18 and FGFR1 were up-regulated in AWBF, whereas ATR and ATF-2 were down-regulated in AWBF (P < 0.05) (Figs 2 and 3, Table 5 ). PCR, this study validated the common amplifications of four such candidates, namely ATR, ATF-2, CLDN18 and FGFR1.
Many genes of the AWBFs-pure BAC signature belonged to the MAPK pathway [FGFR1, met proto-oncogene (MET), FOS: FBJ murine osteosarcoma viral oncogene homolog], FGFR1 and MET were dysregulated in a sense that could preferentially activate elk-related tyrosine kinase in all the heterogeneous AWBFs compared with pure BAC. The predominant signalling pathway activated downstream of FGFRs in development seems to be MAPK signalling [4] , and although it is incompletely understood, current evidence points to the importance of differential effects of MAPK signalling in determining the cellular response of FGFR activation. The downstream effect of MAPK signalling is mostly cell proliferation. Research has suggested that FGFR1 is an oncogene. Analysis of the effects of FGFR1 activation on mammary epithelial cells in vitro demonstrated that FGFR1 promotes epithelial cell proliferation, survival, migration, invasion and epithelial-mesenchymal transition [5] . FGFR1 is up-regulated in prostate cancer [6] , bladder cancer [7] and breast cancer [8] , and is frequently overexpressed in non-small cell lung cancer (NSCLC) [9] ; FGFR1 expression is correlated with a 3.5-fold enhanced risk of developing metastatic disease as compared with 2-fold for FGFR4 and 3.1-fold for EGFR in NSCLC [10] . In the present study, the data on mRNA levels show that FGFR1 expression is significantly higher in AWBFs than in BAC, suggesting that FGFR1 plays an important role in BAC progression.
The claudin family of tight junction strands (TJs) consists of 23 transmembrane proteins that exhibit distinct tissue-and development-specific expressions. These proteins can form homodimers or heterodimers to produce paired strands connecting adjacent cells, thereby determining the characteristic permeability properties of different epithelial tissues. Precise identification of the regulators of claudin expression and localization in specific areas and that of the contribution of each isoform to cell and organ physiology are essential. The best described of these isoforms is claudin-1, which has been identified as a target of the Wnt/h-catenin pathway [11] . Overexpression of claudin-1 in human tumours promotes cell invasion [12] . Claudin-7, another claudin isoform, was also recently shown to be overexpressed in human colon cancer samples. It displays a peculiar expression profile in epithelial cells of several organs, largely outside the TJ area and along the basolateral membrane [13] . The literature about the status of claudins in various cancers is constantly expanding, and in contrast to the general assumption that claudin expression would decrease during tumorigenesis as TJs are lost during cellular transformation, claudin expression seems to change in a tissue-specific manner. Tan et al. [10] showed that the expression and distribution of claudin-1 are associated with cell dissociation status in pancreatic cancer cells through MAPK-2 activation. In contrast, claudin-7 has been found to be decreased in invasive ductal carcinomas [14] , head and neck cancer [15] and metastatic breast cancer [16, 17] . On the other hand, claudin-3 and claudin-4 are frequently elevated in various cancers, including pancreatic ductal adenocarcinoma, and ovarian cancer [18] , whereas hepatocellular and renal carcinomas expressed lower levels of claudin-4 and claudin-5. Reduced expression of claudin-2 was also seen in breast and prostatic carcinomas, and expressions of claudin-1 and claudin-7 that were undetectable in normal cervical squamous epithelium increased in cervical neoplasia [19] . Interestingly, recent studies have shown that the expression of certain claudins, especially claudin-1 and claudin-4, increases during metastasis and that genetic inhibition of their expression significantly affects the metastatic abilities of cancer cells in a tissue-specific manner [20, 21] . To the best of our knowledge, CLDN18 expression has not been studied in AWBFs to date. The present study data on mRNA levels have shown that CLDN18 expression is significantly higher in AWBFs than in BAC, suggesting that its overexpression might be crucial in invasion and metastasis. This finding was validated by real-time RT-PCR for CLDN18, and the finding that CLDN18 is significantly overexpressed in AWBFs is currently being analysed in a larger cohort. Intuitively, the mechanism by which decreased claudin expression might lead to compromised TJ function and neoplasia is easy to comprehend, but the manner by which increased claudin expression contributes to neoplastic progression, as described here and in other studies, is less clear. One plausible mechanism is that upregulation or aberrant tissue expression of certain claudins may contribute to neoplasia by directly altering the structure and function of TJs. Furthermore, that claudins may also affect cell signalling pathways has been postulated. Claudin proteins are likely involved in signalling pathways via binding domains to ZO-1 at their carboxyl terminus. Cell-cell adhesion proteins are known to play an important role in cellular transformation when displaced from their normal membrane localization and could serve as oncogenic molecules. The best studied molecule is β-catenin, which becomes oncogenic although it serves as a cell-cell adhesion molecule when expressed in its normal cellular localization [22] . A similar functional heterogeneity could be postulated for claudins, but further studies are needed to support this claim.
ATF-2 seems to be a more interesting gene: it plays diverse roles in mammalian cells. Research has shown that the level of ATF-2 mRNA in several types of human cancers, such as gastric cancer, colon colour and prostate cancer, is high and that its overexpression enhances cell proliferation. Analysis of >500 melanoma tumours revealed that nuclear localization of ATF-2 coincides with poor prognosis [23] . However, evidence supporting the hypothesis that ATF-2 is oncogenic and may, under specific conditions, elicit tumour suppressor activities comes from independent studies in skin and mammary tumours. In MCF-7 cells, the promising anti-cancer agent DIM (3, diindolylmethane, derived from Brassica vegetables) activates both the c-Jun Nterminal kinase (JNK) and p38 pathways, resulting in c-Jun and ATF-2 phosphorylation as well as subsequent augmentation of binding of the c-Jun-ATF-2 homodimers and heterodimers to the proximal regulatory element of the interferon-γ promoter. In the human leukaemia cell line HL60, a combination of antioxidants with 1,25-dihydroxyvitamin D3 induces the activation of the JNK pathway in differentiating HL60 cells, followed by increased phosphorylation of c-Jun and ATF. The ATF-2 gene is located in human chromosome 2p32. Chromosome 2q is frequently deleted in several types of human cancers, including lung cancer (35%), neuroblastoma (30%) and breast cancer. In the present study, the gene encoding ATF-2 was significantly down-regulated in AWBF tissues when compared with the pure BAC samples, and the change in the expression level was statistically significant. ATF-2 decreased as BAC progressed to AWBFs. ATF-2 expression is likely associated with the early steps of BAC carcinogenesis, with decreasing levels of expression occurring in AWBFs. This gene represents a potentially useful marker for the early detection of AWBFs.
ATR, another gene of interest that may prove to be a therapeutic target, was found to be more lowly expressed in AWBF. It is a gene dose-dependent tumour suppressor in specific genetic backgrounds [24] . The ATR kinase is a central regulator of the replication checkpoint. Loss of this checkpoint protein causes replication fork collapse and chromosomal rearrangements that may ultimately predispose affected individuals to cancer. Defective ATR pathway signalling could result in DNA breakage at these sites and thus lead to cancer-specific chromosomal aberrations [25] .
CONCLUSION
Gene expression analysis of a limited series of BAC and AWBFs reveals a large number of new genes that are differentially expressed in these tumours, with excellent correlation with the data in PCR tests. The findings in this study provide the evidence of extensive molecular differences in gene expression between these two histogenetically related tumours. Expansion of future series to a larger number of specimens, as done in the present study for four new markers, may prove valuable for characterization of these candidate genes as both diagnostic markers and therapeutic targets. The MAPK pathway, which seemed to be preferentially promoted in this tumour, also needs further investigation to determine whether these specificities have a role in the development of AWBF from pure BAC.
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